Related Experiment Video
Updated: Jun 13, 2026
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
[Multiparameter flow cytometric evaluation of bone marrow involvement in B cell non-Hodgkin's lymphoma]
Sui-Gui Wan1, Xue-Jing Sun, Wu-Han Hui
1Department of Hematology, Xuanwu Hospital, Capital University of Medical Sciences, Beijing 100053, China.
Insights
Multiparameter flow cytometry (MPFC) is more sensitive than bone marrow aspiration cytomorphology for detecting bone marrow involvement in B cell Non-Hodgkin's lymphoma (B-NHL). MPFC aids in evaluating clinical outcomes and predicting survival in B-NHL patients.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Accurate detection of bone marrow involvement is crucial for staging and treatment of B cell Non-Hodgkin's lymphoma (B-NHL).
- Traditional cytomorphology of bone marrow aspiration (BMA) may have limitations in sensitivity for detecting minimal residual disease.
Purpose of the Study:
- To compare the clinical utility of multiparameter flow cytometry (MPFC) and cytomorphology of BMA in identifying bone marrow infiltration in B-NHL patients.
- To assess the prognostic value of MPFC-detected bone marrow involvement on patient survival.
Main Methods:
- Analyzed 96 bone marrow samples from B-NHL patients using MPFC with CD45/SSC and CD20/SSC gating, along with kappa and lambda light chain antibodies.
- Compared MPFC results with conventional cytomorphologic analysis of BMA.
- Correlated bone marrow involvement status with 3-year and 4-year overall survival rates.
Main Results:
- MPFC detected bone marrow involvement in 39.6% of cases, significantly higher than the 12.5% detected by cytomorphology (p<0.05).
- All 12 cases positive by cytomorphology were also positive by MPFC.
- A significant difference in 4-year overall survival was observed between MPFC-negative (73.18%) and MPFC-positive (44.13%) patients (p<0.05).
Conclusions:
- MPFC demonstrates superior sensitivity compared to BMA cytomorphology for detecting bone marrow involvement in B-NHL.
- MPFC-detected bone marrow involvement is a significant prognostic factor, impacting 4-year overall survival.
- MPFC is a valuable tool for clinical evaluation and prognosis prediction in B-NHL patients.
Abstract:
The objective of study was to evaluate the clinical values of multiparameter flow cytometry (MPFC) and cytomorphology of bone marrow aspiration(BMA) in detecting bone marrow involvement in patients with B cell Non-Hodgkin's lymphoma (B-NHL). 96 bone marrow samples from the patients with B-NHL were measured by MPFC using CD45/SSC and CD20/SSC gating strategy combined with anti-kappa and anti-lamda monoclonal antibodies, and then compared with results acquired by cytomorphologic analysis of BMA. The results showed that the bone marrow involvement was confirmed by MPFC in 38 cases (39.6%), while it was detected by cytomorphologic analysis of BMA only in 12 cases (12.5%). There was a significant difference between the two methods (p<0.05). 12 positive cases detected by cytomorphologic analysis of BMA were also positive by MPFC. There was no difference of 3-year overall survival rate between negative and positive cases detected by MPFC, but their 4-year overall survival rate was 73.18+/-6.65% and 44.13%+/-19.55% respectively (p<0.05). It is concluded that the MPFC is a more sensitive method for detecting bone marrow involvement in patients with B-NHL than cytomorphologic analysis of BMA. The 4-year overall survival rate of the patients without bone marrow involvement was significant higher than those of patients with bone marrow involvement. Bone marrow involvement in B-NHL detected by MPFC can be useful for clinical evaluation and prognosis prediction.
